Premium
Regulation of p85α phosphatidylinositol‐3‐kinase expression by peroxisome proliferator‐activated receptors (PPARs) in human muscle cells
Author(s) -
Rieusset Jennifer,
Roques Marina,
Bouzakri Karim,
Chevillotte Emmanuel,
Vidal Hubert
Publication year - 2001
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(01)02674-6
Subject(s) - peroxisome proliferator activated receptor , phosphatidylinositol , activator (genetics) , retinoid x receptor , medicine , endocrinology , receptor , retinoic acid , nuclear receptor , peroxisome , chemistry , kinase , microbiology and biotechnology , biology , transcription factor , biochemistry , gene
Regulation of p85α phosphatidylinositol‐3‐kinase (p85αPI‐3K) expression by peroxisome proliferator‐activated receptor (PPAR) activators was studied in human skeletal muscle cells. Activation of PPARγ or PPARβ did not modify the expression of p85αPI‐3K. In contrast, activation of PPARα increased p85αPI‐3K mRNA. This effect was potentiated by 9‐ cis ‐retinoic acid, an activator of RXR. Up‐regulation of p85αPI‐3K gene expression resulted in a rise in p85αPI‐3K protein level and in an increase in insulin‐induced PI3‐kinase activity. According to the role of p85αPI‐3K in insulin action, these results suggest that drugs with dual action on both PPARγ and PPARα can be of interest for the treatment of insulin resistance.